First Trust Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

First Trust Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-82,845	Closed	-$950K	–	2453
2023 Q3	$950K	Sell	82,845 -26,071	-24%	-$501K	﹤0.01%	1981
2023 Q2	$2.76M	Buy	+108,916	New	+$3.39M	﹤0.01%	1550
2022 Q2	–	Sell	-24,653	Closed	-$481K	–	2630
2022 Q1	$481K	Sell	24,653 -33,082	-57%	-$502K	﹤0.01%	2265
2021 Q4	$942K	Buy	57,735 +2,191	+4%	+$36.5K	﹤0.01%	2087
2021 Q3	$1.55M	Buy	55,544 +35,210	+173%	+$1M	﹤0.01%	1868
2021 Q2	$603K	Sell	20,334 -52,682	-72%	-$1.52M	﹤0.01%	2221
2021 Q1	$2.04M	Buy	73,016 +39,682	+119%	+$1.1M	﹤0.01%	1718
2020 Q4	$945K	Sell	33,334 -22,451	-40%	-$582K	﹤0.01%	1915
2020 Q3	$1.4M	Sell	55,785 -3,233	-5%	-$84.8K	﹤0.01%	1576
2020 Q2	$1.44M	Buy	+59,018	New	+$1.16M	﹤0.01%	1548
2019 Q2	–	Sell	-18,371	Closed	-$290K	–	2521
2019 Q1	$290K	Buy	+18,371	New	+$319K	﹤0.01%	2279

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Trust Advisors's RVNC Position: Q4 2023 in Review

First Trust Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2023, closing a stake of 82,845 shares — an estimated $950K sold.

First Trust Advisors first reported a position in RVNC in Q1 2019 and held it in 11 quarters. The position peaked at $2.76M in Q2 2023. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2023.

First Trust Advisors reported no remaining Revance Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
First Trust Advisors sold 82,845 Revance Therapeutics, Inc. shares in Q4 2023, an estimated $950K.
First Trust Advisors first reported a position in Revance Therapeutics, Inc. in Q1 2019 and held it in 11 quarters.
First Trust Advisors's Revance Therapeutics, Inc. position peaked at $2.76M in Q2 2023.
193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2023.

Based on First Trust Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.